Profile data is unavailable for this security.
About the company
Jasper Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics targeting mast cell driven diseases, such as Chronic Spontaneous Urticaria (CSU) and Chronic Inducible Urticaria (CIndU). It also has ongoing programs in diseases where targeting diseased hemopoietic stem cells can provide benefits, such as Lower to Intermediate Risk Myelodysplastic Syndrome (LR-MDS), and stem cell transplant conditioning regimens. The Company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (c-Kit) receptor on mast and stem cells. The SCF/c-Kit pathway is a survival signal for mast cells. It is also developing briquilimab as a one-time conditioning therapy for severe combined immunodeficiency (SCID) patients undergoing a second stem cell transplant for which it is conducting a Phase 1/2 clinical trial.
- Revenue in USD (TTM)0.00
- Net income in USD-64.47m
- Incorporated2019
- Employees45.00
- LocationJasper Therapeutics Inc2200 Bridge Pkwy Suite #102REDWOOD CITY 94065United StatesUSA
- Phone+1 (650) 549-1400
- Fax+1 (302) 636-5454
- Websitehttps://www.jaspertherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amarin Corporation plc (ADR) | 277.46m | -52.61m | 344.68m | 275.00 | -- | -- | -- | 1.24 | -0.1045 | -0.1045 | -- | -- | -- | -- | -- | 1,008,927.00 | -- | -4.48 | -- | -6.54 | 63.61 | 75.70 | -18.96 | -8.59 | -- | -- | -- | -- | -16.87 | 6.01 | 44.13 | -- | 55.83 | -- |
| CytomX Therapeutics Inc | 101.21m | -569.00k | 347.46m | 120.00 | -- | -- | 216.35 | 3.43 | -0.0191 | -0.0191 | 1.37 | -0.7049 | 0.4375 | -- | 5.14 | 843,450.00 | -0.246 | -21.53 | -0.7382 | -32.32 | -- | -- | -0.5622 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Nautilus Biotechnology Inc | 0.00 | -67.44m | 347.77m | 167.00 | -- | 1.40 | -- | -- | -0.5402 | -0.5402 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -21.26 | -- | -21.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
| Heron Therapeutics Inc | 127.04m | -110.56m | 351.77m | 126.00 | -- | -- | -- | 2.77 | -0.8695 | -0.8695 | 0.9494 | -0.2261 | 0.5367 | 1.35 | 2.26 | 1,008,286.00 | -46.70 | -53.55 | -71.00 | -71.24 | 48.75 | 52.52 | -87.02 | -170.12 | 1.84 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Precigen Inc | 6.23m | -95.90m | 353.39m | 202.00 | -- | 2.94 | -- | 56.77 | -0.3933 | -0.3933 | 0.0255 | 0.476 | 0.0339 | -- | 6.62 | 30,816.83 | -52.26 | -31.50 | -72.27 | -38.63 | 1.70 | 44.00 | -1,540.63 | -232.32 | -- | -- | 0.00 | -- | -76.87 | -47.16 | -20.22 | -- | -48.30 | -- |
| Ocugen Inc | 6.04m | -63.08m | 357.68m | 65.00 | -- | 8.79 | -- | 59.26 | -0.2616 | -0.2616 | 0.0247 | 0.1581 | 0.0697 | -- | -- | 92,861.54 | -72.85 | -83.56 | -91.66 | -97.79 | -- | -- | -1,045.03 | -2,921.94 | -- | -- | 0.0646 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Skye Bioscience Inc | 0.00 | -37.64m | 358.92m | 11.00 | -- | -- | -- | -- | -5.69 | -5.69 | 0.00 | -0.1726 | 0.00 | -- | -- | 0.00 | -357.65 | -232.67 | -- | -- | -- | -- | -- | -- | -- | -43.27 | 1.95 | -- | -- | -- | -93.23 | -- | 23.38 | -- |
| Solid Biosciences Inc | 0.00 | -96.02m | 360.20m | 88.00 | -- | 1.54 | -- | -- | -4.84 | -4.84 | 0.00 | 6.20 | 0.00 | -- | -- | 0.00 | -45.16 | -49.99 | -49.47 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0133 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Jasper Therapeutics Inc | 0.00 | -64.47m | 361.90m | 45.00 | -- | 3.41 | -- | -- | -6.19 | -6.19 | 0.00 | 7.03 | 0.00 | -- | -- | 0.00 | -90.00 | -- | -104.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.06 | -- | -- | -- |
| Erasca Inc | 0.00 | -125.04m | 362.28m | 126.00 | -- | 0.9971 | -- | -- | -0.8327 | -0.8327 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -27.48 | -- | -29.94 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.50 | -- | -- | -- |
| Nature's Sunshine Products Inc | 445.32m | 15.08m | 363.40m | 814.00 | 25.03 | 2.37 | 12.87 | 0.816 | 0.7715 | 0.7715 | 22.78 | 8.16 | 1.86 | 1.84 | 38.84 | 547,076.20 | 6.85 | 6.57 | 10.02 | 9.41 | 72.11 | 72.69 | 3.69 | 3.74 | 1.29 | -- | 0.00 | 27.72 | 5.55 | 4.07 | 3,965.64 | -- | 16.73 | -- |
| Tenaya Therapeutics Inc | 0.00 | -124.08m | 367.46m | 140.00 | -- | 2.29 | -- | -- | -1.68 | -1.68 | 0.00 | 2.04 | 0.00 | -- | -- | 0.00 | -55.21 | -- | -61.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Harrow Inc | 130.19m | -24.41m | 368.83m | 315.00 | -- | 5.18 | -- | 2.83 | -0.7448 | -0.7448 | 3.99 | 2.01 | 0.5546 | 4.55 | 6.13 | 413,311.10 | -10.40 | -10.86 | -12.14 | -12.71 | 69.55 | 70.75 | -18.75 | -15.35 | 2.61 | 0.0445 | 0.7223 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Aura Biosciences Inc | 0.00 | -76.41m | 378.71m | 88.00 | -- | 1.67 | -- | -- | -1.93 | -1.93 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -31.90 | -- | -33.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Esperion Therapeutics Inc | 116.33m | -209.25m | 386.38m | 240.00 | -- | -- | -- | 3.32 | -2.11 | -2.11 | 1.13 | -3.85 | 0.5128 | 0.8583 | 2.83 | 484,725.00 | -92.23 | -69.45 | -203.94 | -101.81 | 62.81 | -- | -179.87 | -147.44 | 0.867 | -2.85 | -- | -- | 54.14 | -- | 10.45 | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to Jasper Therapeutics Inc's reporting currency: US Dollar USD
34.72%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Velan Capital Investment Management LPas of 08 Feb 2024 | 1.19m | 7.89% |
| Soleus Capital Management LP (Investment Management)as of 31 Dec 2023 | 987.10k | 6.55% |
| Avidity Partners Management LPas of 18 Mar 2024 | 760.00k | 5.05% |
| Octagon Capital Advisors LPas of 31 Dec 2023 | 446.81k | 2.97% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 406.66k | 2.70% |
| Opaleye Management, Inc.as of 31 Dec 2023 | 398.53k | 2.65% |
| Kingdon Capital Management LLCas of 31 Dec 2023 | 354.00k | 2.35% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 293.01k | 1.95% |
| Nantahala Capital Management LLCas of 31 Dec 2023 | 222.83k | 1.48% |
| Woodline Partners LPas of 31 Dec 2023 | 173.30k | 1.15% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
